Administration of VEGF-A165b, or manipulation of VEGF-A splicing to promote VEGF-A165b expression (such as with SRPK1 inhibitors), has been shown to be therapeutic in many tumor models through inhibition of VEGF-Axxxa mediated angiogenesis [108,109]. The gene discussed is VEGFA; the disease is neoplasm.